Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to assets ratio high or low?
The debt to assets ratio of 16.17% is 18% below its 5-year average of 19.64%, near the low end of its 5-year range (15.03%–29.64%).
As of the fiscal period ended Tuesday, June 30, 2026. 2.94% above its 12-month average of 15.71%.
Reported quarterly debt to assets ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 16.17%.
DEBT TO ASSETS RATIO
16.17%
DEBT TO ASSETS RATIO AVG TTM
15.71%
DEBT TO ASSETS RATIO AVG 3Y
18.58%
DEBT TO ASSETS RATIO AVG 5Y
19.64%
DEBT TO ASSETS RATIO AVG 10Y
N/A
DEBT TO ASSETS RATIO AVG 15Y
N/A
DEBT TO ASSETS RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
+2.94%
CURRENT VS 3Y AVG
-12.98%
CURRENT VS 5Y AVG
-17.68%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.09%
median of 874 covered companies
CURRENT VS SECTOR MEDIAN
+17864.07%
vs the sector median at left
PROCEPT BioRobotics Corporation
Market Cap
$986.45M
Debt to Assets Ratio
16.17%
TTM Avg
15.71%
3Y Avg
18.58%
5Y Avg
19.64%
Market Cap
$988.20M
Debt to Assets Ratio
0.01%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$991.38M
Debt to Assets Ratio
0.28%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$992.62M
Debt to Assets Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$979.80M
Debt to Assets Ratio
0.33%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$966.02M
Debt to Assets Ratio
0.02%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.01B
Debt to Assets Ratio
0.01%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | DEBT TO ASSETS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| PROCEPT BioRobotics Corporation (PRCT) | $986.45M | 16.17% | 15.71% | 18.58% | 19.64% |
| LB Pharmaceuticals Inc Common Stock (LBRX)vs › | $988.20M | 0.01% | N/A | N/A | N/A |
| MeiraGTx Holdings plc (MGTX)vs › | $991.38M | 0.28% | N/A | N/A | N/A |
| Latigo Biotherapeutics Inc. (LTGO)vs › | $992.62M | N/A | N/A | N/A | N/A |
| Pacira BioSciences, Inc. (PCRX)vs › | $979.80M | 0.33% | N/A | N/A | N/A |
| Vor Biopharma Inc. (VOR)vs › | $998.65M | 0.01% | N/A | N/A | N/A |
| Aktis Oncology, Inc. (AKTS)vs › | $966.02M | 0.02% | N/A | N/A | N/A |
| Immatics N.V. (IMTX)vs › | $1.01B | 0.03% | N/A | N/A | N/A |
| Cullinan Therapeutics, Inc. (CGEM)vs › | $1.01B | 0.01% | N/A | N/A | N/A |
| Savara Inc. (SVRA)vs › | $957.56M | 0.16% | N/A | N/A | N/A |
Debt/Assets
16.2%
Debt/Equity
0.23
Current Ratio
6.55
Interest Coverage
-29.0x
Formula: Debt/Assets = Total Debt / Total Assets × 100
Debt/Assets vs Debt/Equity:
Industry context matters: Capital-intensive industries (utilities, real estate) typically have higher Debt/Assets ratios than tech companies.
Debt/Assets ratio shows what percentage of a company's assets are financed by debt. Compare the current value with the historical chart and peer group to understand leverage over time.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO ASSETS RATIO |
|---|---|
| 2026-06-30 | 16.17% |
| 2026-03-31 | 16.01% |
| 2025-12-31 | 15.45% |
| 2025-09-30 | 15.43% |
| 2025-06-30 | 15.47% |
| 2025-03-31 | 15.37% |
| 2024-12-31 | 15.03% |
| 2024-09-30 | 21.55% |
| 2024-06-30 | 21.64% |
| 2024-03-31 | 21.26% |
| 2023-12-31 | 19.57% |
| 2023-09-30 | 18.93% |
| 2023-06-30 | 29.64% |
| 2023-03-31 | 28.13% |
| 2022-12-31 | 25.00% |
| 2022-09-30 | 23.63% |
| 2022-06-30 | 17.24% |
| 2022-03-31 | 16.78% |
| 2021-12-31 | 16.05% |
| 2021-09-30 | 15.46% |
| 2021-06-30 | 28.62% |
| 2020-12-31 | 43.47% |
